Press Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Aug 11, 2023
Acquisition of Spyre's assets and concurrent oversubscribed $210.0 million private investment positions the company to advance a potentially best-in-class inflammatory bowel disease (IBD)...
-
Jul 27, 2023
Global rights to pegzilarginase in development for Arginase 1 Deficiency sold to Immedica Pharma for $15 million upfront cash proceeds and up to $100 million of contingent milestone payments...
-
Jun 23, 2023
Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ: AGLE) today announced that, in connection with the acquisition of Spyre Therapeutics, Inc. ("Spyre"), a majority of the independent members of...
-
Jun 22, 2023
Acquisition of Spyre and concurrent oversubscribed $210 million private investment positions the company to advance a leading inflammatory bowel disease (IBD) portfolio Spyre, the second spinout...
Eric McIntyre
eric.mcintyre@spyre.com